



REVASC ClinicalTrials.gov, Identifier: NCT01924962

Recovery of Left Ventricular Function in Coronary Chronic Total Occlusion

Kambis Mashayekhi



University Heart center Freiburg - Bad Krozingen

Director of CTO and High Risk Angioplasty



Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship

Consulting Fees/Honoraria

Company

Ashai Intecc, Boston, Medtronic, Teleflex, Cardinal Health, Abboth, Biotronik, Terumo, AstraZeneca, Daiichi Sankyo

Grant/Research Support

REVASC was sponsored by Cordis





REVASC Trial



 \mathbf{O}

Recovery of Left Ventricular Function After Stent Implantation in Chronic Total cclusion of Coronary Arteries :

Background

 Whether percutaneous coronary intervention (PCI) in chronic occluded coronary arteries (CTO) may improve outcomes compared to optimal medical therapy (OMT) is still controversial.


Objective

 We evaluated whether PCI of CTO (CTO-PCI) improves regional left ventricular function in addition to PCI of relevant coexisting non-CTO vessels (no-CTO-PCI).





Primary Endpoint: Segmental wall thickening (SWT) measured by cMRI after 6 months



Modified from Kirschbaum SW et al, JACC Cardiovasc Imaging. 2010 Jun;3(6):614-22





HERZZENTRUM

Study endpoints

• Primary endpoint:

- Change in segmental wall thickening (SWT) in the CTO territory according to the 17-segment model between baseline and follow-up at 6 months

Secondary endpoints:

- Changes in LV end-diastolic and end-systolic volume indices and left ventricular ejection fraction (LVEF)

• Clinical outcomes:

- MACE at 12 months was defined as all-cause death, myocardial infarction and any clinically driven repeat revascularization.







Patient selection

Major inclusion criteria

- CTO with an estimated reference vessel diameter of 2.5-4.0mm.
- Clinical symptoms or positive functional study for ischemia

Exclusion criteria

- Left ventricular ejection fraction < 25%
- Acute coronary syndrome < 72 hours preceding the index procedure
- Contraindications to cMRI







Estimation of sample size

• Hypothesis:

15%-recovery of SWT with CTO-PCI versus a 2%-recovery with No-CTO-PCI at a common standard deviation of 30%.

• Goal: 80% power, level of significance 5%

Sample size: 85 patients per study arm


Recruitment:

200 patients (to account for losses to follow-up)





Study flow of REVASC





Baseline demographic and angiographic characteristics

	no-CTO-PCI	CTO-PCI	p Value
	(n = 104)	(n = 101)	
Age (years)	68 [61 - 74]	65 [57 - 72]	0.02
Male gender	90 (86.5)	91 (90.1)	0.43
Diabetes	31 (29.8)	32 (31.6)	0.77
LVEF (%)	59.6 [45.8 - 64.3]	54.7 [42.9 - 65.1]	0.48
Previous PCI	33 (31.7)	28 (27.7)	0.53
Previous myocardial infarction	38 (36.5)	39 (38.6)	0.76
Previous bypass operation	14 (13.5)	12 (11.9)	0.73



Angiographic characteristics

	no-CTO-PCI (n = 104)	CTO-PCI (n = 101)	p Value
Coronary artery disease 1-vessel disease 2,3-vessel disease	10 (9.6) 94 (90.4)	14 (13.9) 87 (86.1)	0.55
SYNTAX-Score	16 [11 - 21]	14 [9 - 22]	0.33
Residual SYNTAX- Score	11 [8 - 16]	2 [0 - 7]	<0.01
J-CTO Score	2 [1 - 2]	2 [1-3]	0.43
PROGRESS Score	0 [0 – 1]	1 [0-1]	<0.01






Procedural CTO data

	CTO-PCI (n = 101)	
CTO recanalization technique		
antegrade only	61 (60.4)	
retrograde	40 (39.6)	
Technical success on first attempt	87 (86.1)	
Technical success including 2 nd attempts	100 (99.0)	
Procedure time (minutes)	96 [65 – 149]	
Fluoroscopy time (minutes)	37 [20 – 76]	
Radiation dose (µGy*cm ²)	10322 [5725 – 17539]	
Contrast Volume (ml)	280 [200 - 400]	





Primary endpoint:




TCTAP 2018







Primary endpoint:










Primary endpoint:










Secondary endpoint:




TCTAP2018





Major adverse cardiac events at 12 months (death, infarction, any revascularization)









Major adverse cardiac events at 12 months

	no-CTO-PCI	CTO-PCI
	(n = 104)	(n = 101)
MACE	17 (18.2)	6 (5.9)
Death of any cause at 12 months	2 (2.0)	1 (1.0)
Acute myocardial infarction	1 (1.0)	0 (0.0)
Clinically driven repeat revascularization at 12 months:	16 (15.4)	5 (5.0)
CTO vessel	14 (13.5)	3 (3.0)





Conclusion

- In the entire cohort, CTO-PCI did not improve regional or global left ventricular function over no-CTO PCI.
- In the subset of patients without major non-CTO lesions, CTO-PCI was associated with a trend towards larger improvement in segmental wall thickening than no-CTO-PCI.
- In the entire cohort, CTO-PCI resulted in clinical benefit over no CTO-PCI as evidenced by reduced MACE rates at 12 months.



